Literature DB >> 30423430

Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice.

Valentina R Garbarino1, Taylor A Santos2, Anastassia R Nelson3, Wynne Q Zhang4, Corey M Smolik5, Martin A Javors6, Lynette C Daws7, Georgianna G Gould8.   

Abstract

Poorly managed gestational diabetes can lead to severe complications for mother and child including fetal overgrowth, neonatal hypoglycemia and increased autism risk. Use of metformin to control it is relatively new and promising. Yet safety concerns regarding gestational metformin use remain, as its long-term effects in offspring are unclear. In light of beneficial findings with metformin for adult mouse social behavior, we hypothesized gestational metformin treatment might also promote offspring sociability. To test this, metformin was administered to non-diabetic, lean C57BL/6 J female mice at mating, with treatment discontinued at birth or wean. Male offspring exposed to metformin through birth lost social interaction preference relative to controls by time in chambers, but not by sniffing measures. Further, prenatal metformin exposure appeared to enhance social novelty preference only in females. However due to unbalanced litters and lack of statistical power, firm establishment of any sex-dependency of metformin's effects on sociability was not possible. Since organic cation transporter 3 (OCT3) transports metformin and is dense in placenta, social preferences of OCT3 knock-out males were measured. Relative to wild-type, OCT3 knock-outs had reduced interaction preference. Our data indicate gestational metformin exposure under non-diabetic conditions, or lack of OCT3, can impair social behavior in male C57BL6/J mice. Since OCT3 transports serotonin and tryptophan, impaired placental OCT3 function is one common mechanism that could persistently impact central serotonin systems and social behavior. Yet no gross alterations in serotonergic function were evident by measure of serotonin transporter density in OCT3, or serotonin turnover in metformin-exposed offspring brains. Mechanisms underlying the behavioral outcomes, and if with gestational diabetes the same would occur, remain unclear. Metformin's impacts on placental transporters and serotonin metabolism or AMPK activity in fetal brain need further investigation to clarify benefits and risks to offspring sociability from use of metformin to treat gestational diabetes.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1,1-dimethylbiguanide; Autism; Pregnancy; SLC22A3; Serotonin; Social behavior

Mesh:

Substances:

Year:  2018        PMID: 30423430      PMCID: PMC6388691          DOI: 10.1016/j.phrs.2018.11.013

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  82 in total

1.  Association of maternal diabetes with autism in offspring.

Authors:  Anny H Xiang; Xinhui Wang; Mayra P Martinez; Johanna C Walthall; Edward S Curry; Kathleen Page; Thomas A Buchanan; Karen J Coleman; Darios Getahun
Journal:  JAMA       Date:  2015-04-14       Impact factor: 56.272

2.  Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.

Authors:  Caroline A Crowther; Janet E Hiller; John R Moss; Andrew J McPhee; William S Jeffries; Jeffrey S Robinson
Journal:  N Engl J Med       Date:  2005-06-12       Impact factor: 91.245

3.  Pharmacokinetics of metformin during pregnancy.

Authors:  Sara Eyal; Thomas R Easterling; Darcy Carr; Jason G Umans; Menachem Miodovnik; Gary D V Hankins; Shannon M Clark; Linda Risler; Joanne Wang; Edward J Kelly; Danny D Shen; Mary F Hebert
Journal:  Drug Metab Dispos       Date:  2010-01-29       Impact factor: 3.922

4.  Differential patterning of genes involved in serotonin metabolism and transport in extra-embryonic tissues of the mouse.

Authors:  Hsiao-Huei Wu; Sera Choi; Pat Levitt
Journal:  Placenta       Date:  2016-03-30       Impact factor: 3.481

Review 5.  Safety considerations with pharmacological treatment of gestational diabetes mellitus.

Authors:  David Simmons
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

6.  Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders.

Authors:  Paula Krakowiak; Cheryl K Walker; Andrew A Bremer; Alice S Baker; Sally Ozonoff; Robin L Hansen; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2012-04-09       Impact factor: 7.124

7.  OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.

Authors:  Ligong Chen; Yan Shu; Xiaomin Liang; Eugene C Chen; Sook Wah Yee; Arik A Zur; Shuanglian Li; Lu Xu; Kayvan R Keshari; Michael J Lin; Huan-Chieh Chien; Youcai Zhang; Kari M Morrissey; Jason Liu; Jonathan Ostrem; Noah S Younger; John Kurhanewicz; Kevan M Shokat; Kaveh Ashrafi; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-24       Impact factor: 11.205

8.  Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS.

Authors:  Anna Hjorth-Hansen; Øyvind Salvesen; Liv Guro Engen Hanem; Torbjørn Eggebø; Kjell Å Salvesen; Eszter Vanky; Rønnaug Ødegård
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

9.  Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice.

Authors:  Vincent Vialou; Laure Balasse; Jacques Callebert; Jean-Marie Launay; Bruno Giros; Sophie Gautron
Journal:  J Neurochem       Date:  2008-05-30       Impact factor: 5.372

10.  Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study.

Authors:  Joanne E Given; Maria Loane; Ester Garne; Marie-Claude Addor; Marian Bakker; Bénédicte Bertaut-Nativel; Miriam Gatt; Kari Klungsoyr; Nathalie Lelong; Margery Morgan; Amanda J Neville; Anna Pierini; Anke Rissmann; Helen Dolk
Journal:  BMJ       Date:  2018-06-25
View more
  7 in total

1.  Serotonin homeostasis in the materno-foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta.

Authors:  Rona Karahoda; Hana Horackova; Petr Kastner; Andreas Matthios; Lukas Cerveny; Radim Kucera; Marian Kacerovsky; Jurjen Duintjer Tebbens; Alexandre Bonnin; Cilia Abad; Frantisek Staud
Journal:  Acta Physiol (Oxf)       Date:  2020-05-18       Impact factor: 6.311

2.  Dopamine Evokes a Trace Amine Receptor-dependent Inward Current that is Regulated by AMP Kinase in Substantia Nigra Dopamine Neurons.

Authors:  Wei Yang; Adam C Munhall; Steven W Johnson
Journal:  Neuroscience       Date:  2019-12-26       Impact factor: 3.590

3.  Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses.

Authors:  Consolación Garcia-Contreras; Marta Vazquez-Gomez; José Luis Pesantez-Pacheco; Laura Torres-Rovira; Ana Heras-Molina; Teresa Encinas; Susana Astiz; Antonio Gonzalez-Bulnes
Journal:  Biomolecules       Date:  2019-04-29

4.  Metformin Alleviates Autistic-Like Behaviors Elicited by High-Fat Diet Consumption and Modulates the Crosstalk Between Serotonin and Gut Microbiota in Mice.

Authors:  Wenlin Deng; Haoran Ke; Siqi Wang; Zitong Li; Sitao Li; Pinjing Lv; Fang Li; Ye Chen
Journal:  Behav Neurol       Date:  2022-02-17       Impact factor: 3.342

5.  High Affinity Decynium-22 Binding to Brain Membrane Homogenates and Reduced Dorsal Camouflaging after Acute Exposure to it in Zebrafish.

Authors:  Georgianna G Gould; Priscilla A Barba-Escobedo; Rebecca E Horton; Lynette C Daws
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

6.  Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization.

Authors:  Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez
Journal:  Front Mol Neurosci       Date:  2022-08-17       Impact factor: 6.261

7.  Organic Cation Transporters in Psychiatric Disorders.

Authors:  Lynette C Daws
Journal:  Handb Exp Pharmacol       Date:  2021
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.